How big is Blue Water Biotech, Inc.?

As of Jun 18, Blue Water Biotech, Inc. has a market capitalization of 0.70 million and reported net sales of 2.52 million with a net profit of -58.70 million over the latest four quarters.

As of Jun 18, Blue Water Biotech, Inc. has a market capitalization of 0.70 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 2.52 million, while the sum of net profit for the same period is -58.70 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 9.86 million and total assets amounting to 28.46 million.

What does Blue Water Biotech, Inc. do?

Blue Water Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $29 million as of December 2024. Key metrics include a market cap of $0.70 million, a debt-to-equity ratio of 1.83, and a return on equity of -184.29%.

Overview: <BR>Blue Water Biotech, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -29 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 0.70 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.83 <BR>Return on Equity: -184.29% <BR>Price to Book: 0.16<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Blue Water Biotech, Inc.?

Is Blue Water Biotech, Inc. overvalued or undervalued?

As of August 29, 2024, Blue Water Biotech, Inc. is rated as risky due to significant losses and poor financial metrics, including a Price to Book Value of 0.11 and negative EV ratios, despite a volatile stock performance showing a year-to-date return of 376.19%, which is much higher than the S&P 500's 12.22%, but a one-year return of -36.44% compared to the S&P's 17.14%.

As of 29 August 2024, the valuation grade for Blue Water Biotech, Inc. has moved from does not qualify to risky, indicating increased concern regarding its financial health. The company appears to be overvalued given its significant losses and poor financial metrics, including a Price to Book Value of 0.11, an EV to EBIT of -1.72, and an EV to EBITDA of -1.89. <BR><BR>In comparison to peers, Blue Water Biotech's valuation ratios are concerning; for instance, Tonix Pharmaceuticals has an EV to EBITDA of -1.2007, while Cyclerion Therapeutics stands at -1.2082, both of which are better than Blue Water's metrics. The company's recent stock performance has been volatile, with a year-to-date return of 376.19%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the last year with a return of -36.44% compared to the S&P's 17.14%.

Is Blue Water Biotech, Inc. technically bullish or bearish?

As of July 17, 2025, Blue Water Biotech, Inc. shows a mildly bullish trend supported by daily moving averages, but mixed signals from weekly MACD and KST, along with underperformance compared to the S&P 500, suggest a cautious outlook.

As of 17 July 2025, the technical trend for Blue Water Biotech, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands show a mixed signal with weekly mildly bullish and monthly mildly bearish readings. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and year, with a return of -4.15% compared to the S&P's 1.05% for the week, and -36.44% compared to the S&P's 17.14% for the year. Overall, while there are some bullish indicators, the mixed signals and recent performance suggest a cautious outlook.